insights_auto
Why is NVAX down 3.86%?
Dive Deeperchevron_right
NVAX:NASDAQ
Novavax Inc
$10.82
arrow_downward
-3.86%(-0.44) 1D
Oct 19, 3:46:09 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$11.20
High
$11.99
Low
$10.76
Mkt. cap
1.79B
Avg. vol.
7.60M
Volume
4.89M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
Open
$11.20
High
$11.99
Low
$10.76
Mkt. cap
1.79B
Avg. vol.
7.60M
Volume
4.89M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
Benzinga
·
7 hours ago
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
Simply Wall Street
·
1 day ago
Is Novavax (NVAX) Expensive Or Cheap As Investors Reassess Vaccine Risk?
ad-hoc-news.de
·
2 days ago
Novavax stock fell 12.17 percent on October 16, 2026, 15.91 percent below its 52-week high
Reuters
·
2 days ago
Novavax shareholder Shah Capital to step back from activist role
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com